Iron Deficiency in India: A Clinical Reference

This is a clinical and health-system reference on the scale of iron deficiency india, the evidence behind each treatment pathway, and what the numbers mean for hospital procurement. It is not a dosing calculator.

How common is iron deficiency in India, and who does it affect most?

NFHS-5 recorded anaemia, iron deficiency's clinical endpoint, in 57.2% of women aged 15-49 and 67.1% of children aged 6-59 months, both figures higher than the corresponding NFHS-4 (2015-16) numbers. Pregnant women carry the heaviest burden; regional data reviewed by WHO puts anaemia prevalence in Indian pregnant women as high as 88% in some surveyed cohorts.

The prevalence rise between NFHS-4 and NFHS-5 despite a decade of national programming reflects a mix of better case detection and a genuine dietary-iron gap across large parts of the population, not a single cause.

What actually causes iron deficiency at population scale in India?

Inadequate dietary iron intake relative to requirement is the dominant driver, compounded by low bioavailability of iron from a predominantly cereal-based diet and high rates of intestinal parasitism in some regions. Menstrual blood loss adds a second major driver specific to women of reproductive age, and repeated pregnancy without adequate replenishment compounds it further.

Chronic blood loss from other causes (peptic ulcer disease, heavy uterine bleeding, occult GI malignancy in older patients) needs to be ruled out clinically rather than assumed to be purely nutritional, particularly in a patient whose anaemia doesn't respond to iron replacement as expected. In India specifically, this iron deficiency india picture is inseparable from the underlying diet and parasitism burden, which is why supplementation alone rarely closes the gap without addressing intake.

What is the government's actual programme response?

The Ministry of Health and Family Welfare runs Anemia Mukt Bharat, the Intensified National Iron Plus Initiative, targeting six life-stage groups from infants through pregnant and lactating women with a 6x6x6 structure of interventions, delivery mechanisms and monitoring metrics. The programme's stated target is reducing anaemia prevalence across these groups by roughly 3 percentage points a year.

A peer-reviewed evaluation of coverage under the programme's first years (2017-20) found substantial gaps between policy design and actual supplementation reach on the ground, particularly for adolescents and non-pregnant women outside antenatal care contact points.

Oral iron or IV iron: what does the evidence actually say?

Oral iron salts remain first-line for most iron deficiency because they are inexpensive, widely available, and effective when tolerated and absorbed. A Cochrane review found daily oral iron supplementation reduced anaemia risk in pregnant women at term by roughly 70% and iron deficiency at term by roughly 57%, a substantial effect at low cost.

Intravenous iron becomes the clinically appropriate choice specifically when oral iron fails: malabsorption states, inflammatory bowel disease, intolerance severe enough to break adherence, or anaemia severe enough that the slower correction curve of oral therapy isn't acceptable given the clinical timeline, as in late-pregnancy anaemia before delivery. The RAPIDIRON trial, run across Indian sites, specifically compared oral iron against single-dose IV iron in pregnant women to evaluate which reduces low-birth-weight delivery risk more effectively.

What does IV iron therapy cost a hospital, and why does that matter for stocking?

Ferric carboxymaltose and iron sucrose are hospital-administered infusions requiring supervised delivery, unlike oral iron which a patient takes home. This means IV iron is fundamentally a pharmacy-and-day-care-unit stocking decision, not a prescription a patient fills elsewhere.

A hospital that identifies IV-iron-eligible patients (severe antenatal anaemia, dialysis-associated anaemia, inflammatory bowel disease) but doesn't stock the formulation reliably either delays a time-sensitive infusion or sends the patient elsewhere for a therapy that should have been delivered in-house the same day.

Does iron deficiency treatment interact with other common medicines?

Oral iron absorption drops sharply when taken alongside calcium supplements, antacids, proton pump inhibitors, and tetracycline or fluoroquinolone antibiotics, all of which either raise gastric pH or compete for absorption. This is a spacing-and-sequencing issue for a prescriber managing a patient on multiple medications, not a contraindication to combining the underlying conditions' treatments.

IV iron formulations carry a distinct interaction profile centred on infusion-reaction risk rather than absorption competition, and require the observed-administration protocol any hospital day-care or infusion unit already runs for other parenteral medicines.

What does this mean for a hospital's in-house pharmacy?

Iron deficiency treatment spans the full range from a two-rupee-a-tablet oral iron salt to a same-day hospital-administered IV infusion, which means it touches nearly every department from obstetrics to nephrology to general medicine. A hospital that stocks the oral range but not the IV formulations, or vice versa, forces a meaningful share of its own patients to fill part of their treatment outside.

That gap costs continuity of care for a chronic, recurring condition that needs follow-up dosing and monitoring, and it costs the hospital the pharmacy revenue on a therapy line it already diagnosed and started. Our piece on prescription leakage and hospital revenue loss covers this pattern in more depth, managed hospital pharmacy services covers the operating model that closes it, and pharmacy inventory management covers keeping both oral and IV iron stock moving without expiry loss.

Sources

1. 1Coverage of iron and folic acid supplementation in India: progress under the Anemia Mukt Bharat strategy 2017-20 — PMC, National Institutes of Health
2. 2Intensified National Iron Plus Initiative — Operational Guidelines — National Health Mission, Ministry of Health and Family Welfare
3. 3RAPIDIRON: Reducing Anaemia in Pregnancy in India — PMC, National Institutes of Health
4. 4Iron Deficiency Anaemia Assessment, Prevention and Control — World Health Organization
5. 5Guideline: Daily Iron and Folic Acid Supplementation in Pregnant Women — WHO, NCBI Bookshelf
6. 6India's Fight Against Anemia — Press Information Bureau, Government of India

This article is for informational purposes and is intended for clinicians and hospital administrators. It is not a substitute for professional medical advice, diagnosis or treatment, and contains no dosage instructions. Consult a qualified doctor for any individual patient's care.